• Published On : Jan-2018 |
  • Pages : 144 Pages |
  • Format :

Table of Content:

1. Executive Summary
     1.1. Market Overview
     1.2. Market Analysis
     1.3. PMR Analysis and Recommendations

2. Market Introduction
     2.1. Market Definition
     2.2. Market Taxonomy
     2.3. Microbiome Therapeutics Market Overview

3. Market View Point
     3.1. Market Dynamics
            3.1.1. Macro-Economic Factors
            3.1.2. Drivers
            3.1.3. Restraints
            3.1.4. Trends

4. Venture Capital Financing

5. Pipeline Analysis

6. Global Microbiome Therapeutics Market Opportunity Assessment 2018-2025
     6.1. Market Opportunity Assessment (US$ Mn) and Analysis By Indication
            6.1.1. Type 2 Diabetes
                     6.1.1.1. U.S.
                     6.1.1.2. Europe
                     6.1.1.3. Japan
                     6.1.1.4. RoW
            6.1.2. C. difficile infection
                     6.1.2.1. C. difficile Infection
                                6.1.2.1.1. U.S.
                                6.1.2.1.2. Europe
                                6.1.2.1.3. Japan
                                6.1.2.1.4. RoW
                     6.1.2.2. Recurrent C. difficile Infection
                                6.1.2.2.1. U.S.
                                6.1.2.2.2. Europe
                                6.1.2.2.3. Japan
                                6.1.2.2.4. RoW
            6.1.3. Obesity
            6.1.4. Primary Hyperoxyurea

7. Global Microbiome Therapeutics Market Potential
     7.1. Microbiome Therapeutics Market Potential for C. difficile Infection Treatment
     7.2. Microbiome Therapeutics Market Potential for Preterm Birth and Gynecology Conditions
     7.3. Microbiome Therapeutics Market Potential for Diabetes
     7.4. Microbiome Therapeutics Market Potential for Obesity

8. Competition Landscape
     8.1. Company Profiles (Details – Overview, pipeline, Strategy, Recent Developments)
            8.1.1. Microbiome Therapeutics Inc.
            8.1.2. SERES Therapeutics Inc.
            8.1.3. LNC Therapeutics Inc.
            8.1.4. Vedanta Biosciences Inc.
            8.1.5. Enterome SA
            8.1.6. Ferring B.V.
            8.1.7. ViThera Pharmaceuticals Inc.
            8.1.8. Second Genome Therapeutics
            8.1.9. Rebiotix
            8.1.10. Synlogic Inc.
            8.1.11. 4D Pharma Plc.
            8.1.12. Ritter Pharmaceuticals
            8.1.13. AvidBiotics
            8.1.14. Osel Inc.
            8.1.15. OxThera AB
            8.1.16. Evelo Biosciences
            8.1.17. AOBiome LLC
            8.1.18. Immuron Ltd.

9. Assumptions and Acronyms Used

10. Research Methodology


List of Table: 

Table 01: Activities in Microbiome Research Across the Globe (1/2)
Table 02: Activities in Microbiome Research Across the Globe (2/2)
Table 03: Global Microbiome Therapeutics Market Partnership and Collaborations (1/6) 
Table 04: Global Microbiome Therapeutics Market Partnership and Collaborations (2/6) 
Table 05: Global Microbiome Therapeutics Market Partnership and Collaborations (3/6) 
Table 06: Global Microbiome Therapeutics Market Partnership and Collaborations (4/6) 
Table 07: Global Microbiome Therapeutics Market Partnership and Collaborations (5/6) 
Table 08: Global Microbiome Therapeutics Market Partnership and Collaborations (6/6) 
Table 09: Venture Capital Investments in Microbiome Therapeutics (2017) 
Table 10: Venture Capital Investments in Microbiome Therapeutics (2016) (1/3) 
Table 11: Venture Capital Investments in Microbiome Therapeutics (2016) (2/3) 
Table 12: Venture Capital Investments in Microbiome Therapeutics (2016) (3/3) 
Table 13: Venture Capital Investments in Microbiome Therapeutics (2015) (2/3) 
Table 14: Venture Capital Investments in Microbiome Therapeutics (2014)
Table 15: Venture Capital Investments in Microbiome Therapeutics (2013)
Table 16: Venture Capital Investments in Microbiome Therapeutics (2011–2012)
Table 17: Microbiome Therapeutics Pipeline Analysis (1/11)
Table 18: Microbiome Therapeutics Pipeline Analysis (2/11)
Table 19: Microbiome Therapeutics Pipeline Analysis (3/11)
Table 20: Microbiome Therapeutics Pipeline Analysis (4/11)
Table 21: Microbiome Therapeutics Pipeline Analysis (5/11)
Table 22: Microbiome Therapeutics Pipeline Analysis (6/11)
Table 23: Microbiome Therapeutics Pipeline Analysis (7/11)
Table 24: Microbiome Therapeutics Pipeline Analysis (8/11)
Table 25: Microbiome Therapeutics Pipeline Analysis (9/11)
Table 26: Microbiome Therapeutics Pipeline Analysis (10/11)
Table 27: Microbiome Therapeutics Pipeline Analysis (11/11)
Table 28: Global Microbiome Therapeutics Market Opportunity Assessment, By Type 2 Diabetes Indication, 2018-2025
Table 29: Global Microbiome Therapeutics Market Opportunity Assessment, C. difficile Infection, 2018-2025
Table 30: Global Microbiome Therapeutics Market Opportunity Assessment, By ObesityIndication, 2018-2025
Table 31: Global Microbiome Therapeutics Market Opportunity Assessment, By Obesity Indication, 2018-2025
Table 32: Research Programs in the Field Microbiome in Preterm/Premature Birth (1/2)
Table 33: Research Programs in the Field of Microbiome in Preterm/Premature Birth (2/2)
Table 34: Seres Therapeutics Inc. Microbiome Therapeutics Pipeline Analysis
Table 35: Vedanta Biosciences Inc. Microbiome Therapeutics Pipeline Analysis
Table 36: Second Genome Therapeutics Microbiome Therapeutics Pipeline Analysis
Table 37: Rebiotix, Inc. Microbiome Therapeutics Pipeline Analysis
Table 38: Synlogic, Inc. Microbiome Therapeutics Pipeline Analysis
Table 39: 4D Pharma PLC. Microbiome Therapeutics Pipeline Analysis
Table 40: OxThera AB. Microbiome Therapeutics Pipeline Analysis
Table 41: Immuron Ltd IMC. Microbiome Therapeutics Pipeline Analysis
Table 42: Enterome Bioscience SA. Microbiome Therapeutics Pipeline Analysis
Table 43: Evelo Biosciences Inc., Microbiome Therapeutics Pipeline Analysis
Table 44: MicroBiome Therapeutics LLC., Microbiome Therapeutics Pipeline Analysis
Table 45: LNC Therapeutics, SA.  Microbiome Therapeutics Pipeline Analysis 
Table 46: Microbiome Therapeutics, LLC Pipeline Analysis
Table 47: Microbiome Therapeutics, LLC Pipeline Analysis
Table 48: Microbiome Therapeutics, LLC Pipeline Analysis
Table 49: Osel  Inc. Microbiome Therapeutics Pipeline Analysis
Table 50: Ritter Pharmaceuticals Inc. Microbiome Therapeutics Pipeline Analysis
Table 51: AOBiome Microbiome Therapeutics Pipeline Analysis


List of Figure: 

Figure 01: Global Microbiome Therapeutics Market Opportunity By Indication (2025)
Figure 02: Number of Partnerships and Collaboration Deals in Microbiome Therapeutics Market (2010 – 2017)
Figure 03: Partnerships and Collaborations Among Microbiome Industry
Figure 04: Trends in Venture Capital Investments in Microbiome Therapeutics  (2011 – 2017)
Figure 05: Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, by Indication
Figure 06: Distribution of Industry sponsored Pipeline Projects for Microbiome Therapeutics, By Phase
Figure 07: Geographical Distribution of Clinical Trials for Microbiome
Figure 08: Distribution of Microbiome Clinical Trials, By Drug Type 
Figure 09: Number Microbiome Therapeutics Drug Pipeline Projects By Indication (September 2017)
Figure 10: Global Microbiome Therapeutics Market Value (US$ Mn) Opportunity Assessment 2018-2025
Figure 11: Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity Assessment (2018–2025) 
Figure 12: Global Type 2 Diabetes Microbiome Therapeutics Market Opportunity by Region (2025)
Figure 13: Global C. difficile Infection Microbiome Therapeutics Market Opportunity Assessment (2018–2025) 
Figure 14: Global C. difficile Infection Microbiome Therapeutics Market Opportunity by Region (2025)
Figure 15: Global Obesity Microbiome Therapeutics Market Opportunity Assessment (2018–2025) 
Figure 16: Global Obesity Microbiome Therapeutics Market Opportunity by Region (2025)
Figure 17: Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity Assessment (2018–2025) 
Figure 18: Global Primary Hyperoxyurea Microbiome Therapeutics Market Opportunity by Region (2025)
Figure 19: Global CDI Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity 
Figure 20: Incidence of C. difficile Infection Across Major Countries as Percentage of Total Hospital Admissions (2016)
Figure 21: Composition of Microbiome of Reproductive Organs
Figure 22: Number of People(Mn) with Diabetes, By Region (2015 & 2040)
Figure 23: Global Diabetes Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity 
Figure 24: Top Ten Countries/Territories For Diabetes Related Health Expenditure (2015)
Figure 25: Global Obesity Treatment Market (US$ Mn ) 2025 (F) and Microbiome Therapeutics Opportunity
Figure 26: Number of people (Mn) with Obesity (2016 & 2020)
Figure 27: Seres Therapeutics Inc. Microbiome Activity Analysis 
Figure 28: Vedanta Biosciences Microbiome Activity Analysis 
Figure 29: Second Genome Inc. Microbiome Activity Analysis 
Figure 30: Second Genome Therapeutics Pipeline Active and Inactive Programs By Indication
Figure 31: Rebiotix Inc. Microbiome Activity Analysis 
Figure 32: Synlogic Inc. Microbiome Activity Analysis 
Figure 33: 4D pharma PLC.  Microbiome Activity Analysis 
Figure 34: OxThera AB Microbiome Activity Analysis 
Figure 35: OxThera AB Pipeline Programs By Phase
Figure 36: Immuron Ltd. Microbiome Activity Analysis 
Figure 37: Enterome Biosciences SA Microbiome Activity Analysis 
Figure 38: Evelo Biosciences Inc. Microbiome Activity Analysis 
Figure 39: Evelo Biosciences Inc. Pipeline Active and Inactive Programs By Indication
Figure 40: Microbiome Therapeutics Inc. Activity Analysis 
Figure 41: Microbiome Therapeutics Inc. Pipeline, Active and Inactive Programs By Indication
Figure 42: Ferring B.V. Microbiome Activity Analysis 
Figure 43: ViThera Pharmaceuticals, Inc. Microbiome Activity Analysis 
Figure 44: C3J Therapeutics, Inc. Microbiome Activity Analysis 
Figure 45: C3J Therapeutics Inc. Pipeline Active and Inactive Programs By Indication
Figure 46: Second Genome Inc. Microbiome Activity Analysis 
Figure 47: Osel  Pipeline Active and Inactive Programs By Indication
Figure 48: Second Genome Inc. Microbiome Activity Analysis 
Figure 49: Second Genome Inc. Microbiome Activity Analysis 
Figure 50: AOBiome Clinical Pipeline Programs By Indication